Pacer Advisors’s Impax Laboratories, Inc. IPXL Stock Holding History

Pacer Advisors’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-6,059	Closed	-$175K	–	1100
2016 Q2	$175K	Buy	+6,059	New	+$197K	0.03%	859

Other funds holding IPXL

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Hound Partners New York $799M AUM 9.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pacer Advisors's IPXL Position: Q3 2016 in Review

Pacer Advisors sold out of Impax Laboratories, Inc. (IPXL) in Q3 2016, closing a stake of 6,059 shares — an estimated $175K sold.

Pacer Advisors first reported a position in IPXL in Q2 2016 and held it in 1 quarter. The position peaked at $175K in Q2 2016. 196 funds tracked by Wall St. Rank hold IPXL as of Q3 2016.

Pacer Advisors reported no remaining Impax Laboratories, Inc. position as of Q3 2016 after selling out during the quarter.
Pacer Advisors sold 6,059 Impax Laboratories, Inc. shares in Q3 2016, an estimated $175K.
Pacer Advisors first reported a position in Impax Laboratories, Inc. in Q2 2016 and held it in 1 quarter.
Pacer Advisors's Impax Laboratories, Inc. position peaked at $175K in Q2 2016.
196 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q3 2016.

Based on Pacer Advisors's 13F filing for Q3 2016, filed 10 Nov 2016.